VA
LENZ

Verdad Advisers’s LENZ Therapeutics LENZ Stock Holding History

Verdad Advisers’s Portfolio LENZ Stock Details LENZ Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$90.3K Buy
+15,900
New +$128K 0.09% 192

Other funds holding LENZ

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
AWG
Alpha Wave Global New York $6.24B AUM 59.73% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
VVM
Versant Venture Management San Francisco, California $163M AUM 240.43% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Squarepoint
Squarepoint New York $90.5B AUM 33.95% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $71.2B AUM 41.74% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
7IH
72 Investment Holdings Stamford, Connecticut $50M AUM 647.58% 1-Year Est. Return

Verdad Advisers's LENZ Position: Q2 2026 in Review

Verdad Advisers opened a new position in LENZ Therapeutics (LENZ) in Q2 2026: 15,900 shares worth $90.3K. The stake represents 0.09% of the portfolio and ranks #192 among its holdings.

144 funds tracked by Wall St. Rank hold LENZ as of Q2 2026.

  • Verdad Advisers held 15,900 shares of LENZ Therapeutics worth $90.3K as of Q2 2026.
  • LENZ Therapeutics was a new Verdad Advisers position in Q2 2026.
  • LENZ Therapeutics made up 0.09% of Verdad Advisers's portfolio in Q2 2026, its #192 holding.
  • 144 funds tracked by Wall St. Rank held LENZ Therapeutics as of Q2 2026.

Based on Verdad Advisers's 13F filing for Q2 2026, filed 14 Aug 2026.